Here's Why Morgan Stanley Analysts Downgraded Novo Nordisk's Stock
1. Morgan Stanley downgraded NVO to 'underweight' due to GLP-1 concerns. 2. Price target cut from $59 to $47, reflecting market pressures. 3. Stagnating prescriptions for Ozempic and Wegovy are significant issues. 4. Upcoming trial results for Alzheimer's treatments may disappoint. 5. NVO shares have lost a third of their value this year.